Floatz logo

ISOCYCLOPHOSPHAMIDE

B-Cell Non-Hodgkin Lymphoma

Shanghai Junshi Bioscience Co., Ltd.Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

305 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
ANTI-CD20/CD3 MONOCLONAL ANTIBODY REGN1979
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
CYTARABINE
Children's Cancer Group, China
Phase 4BBB
Camustine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB

View all 50 →

Same molecule, other indications

ISOCYCLOPHOSPHAMIDE is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
Hodgkins lymphomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →